Click Therapeutics & Indivior To Develop, Commercialize Novel Prescription Digital Therapeutics For Addiction Treatment 

Digital therapeutics company Click Therapeutics and Indivior, a specialty pharmaceutical firm, signed a collaboration agreement for the development and commercialization of prescription digital therapeutics to treat addiction disorders.;;

The first project under the collaboration will focus on opioid use disorder and use a novel mobile application called CT-102 to close gaps in OUD treatment. The companies said CT-102 works alongside pharmacotherapy and combines evidence-based behavioral therapy with tailored neuromodulatory interventions using Click’s artificial intelligence-enabled platform to deliver individualized care to each consumer.;

Under the agreement, Click will lead development using its end . . .